Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kronos Bio, Inc. KRON
$1.73
-$0.03 (-1.70%)
На 18:03, 12 мая 2023
+651.45%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
107768287.00000000
-
week52high
5.74
-
week52low
1.20
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.43366800
-
EPS
-2.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 28 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2021 г. |
| HC Wainwright & Co. | Buy | 24 июн 2021 г. | |
| Berenberg | Buy | 14 сент 2022 г. | |
| Goldman Sachs | Buy | Buy | 10 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 09 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| DiMartino Jorge | D | 219478 | 18657 | 12 дек 2022 г. |
| Dinsmore Christopher | D | 162936 | 9138 | 12 дек 2022 г. |
| Al-Wakeel Yasir B. | A | 40000 | 40000 | 25 июл 2022 г. |
| Al-Wakeel Yasir B. | A | 216841 | 53600 | 25 июл 2022 г. |
| Dinsmore Christopher | A | 172074 | 43550 | 25 июл 2022 г. |
| Kosacz Barbara | A | 791624 | 53600 | 25 июл 2022 г. |
| DiMartino Jorge | A | 238135 | 60300 | 25 июл 2022 г. |
| Yang Taiyin | A | 17000 | 17000 | 22 июн 2022 г. |
| Yang Taiyin | A | 11333 | 11333 | 22 июн 2022 г. |
| De Backer Marianne | A | 17000 | 17000 | 22 июн 2022 г. |
Новостная лента
5 Hot Penny Stocks To Watch This Week With Big News
PennyStocks
09 янв 2023 г. в 09:02
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Kronos Bio's stock rallies after announcing drug-discovery deal with Roche
Market Watch
09 янв 2023 г. в 08:23
Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's ROG, -0.46% Genentech. Kronos has a drug discovery platform that will be used to support Genentech's research in small-molecule drugs for cancer.
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
Zacks Investment Research
12 дек 2022 г. в 11:17
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Kronos Bio Announces Participation in Upcoming Investor Conferences
GlobeNewsWire
22 ноя 2022 г. в 16:05
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
Zacks Investment Research
22 ноя 2022 г. в 11:17
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.